Abscobal Effect of Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer

Affiliations

¹ Volkan Aslan, MD, Osman Sütcüoğlu, MD, Ahmet Özet, MD, Nuriye Özdemir, MD, Ozan Yazıcı, MD, Department of Medical Oncology, Gazi University, Ankara, Turkey.

Comment

Volkan Aslan et al. J Clin Oncol. 2022.

. 2022 Jul 1;40(19):2177-2178.

doi: 10.1200/JCO.22.00084. Epub 2022 Apr 29.

¹ Volkan Aslan, MD, Osman Sütcüoğlu, MD, Ahmet Özet, MD, Nuriye Özdemir, MD, Ozan Yazıcı, MD, Department of Medical Oncology, Gazi University, Ankara, Turkey.

No abstract available

Comment on

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
O'Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A, Bulat I, Meniawy TM, Bagameri A, Wang EW, Doger de Speville Uribe B, Hegg R, Ortuzar Feliu W, Ancukiewicz M, Lugowska I. O'Malley DM, et al. J Clin Oncol. 2022 Mar 1;40(7):762-771. doi: 10.1200/JCO.21.02067. Epub 2021 Dec 21. J Clin Oncol. 2022. PMID: 34932394 Free PMC article. Clinical Trial.